A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Locally Advanced Breast Cancer
Interventions: DRUG: U3-1402
Sponsor: SCRI Development Innovations, LLC
Collaborators: Daiichi Sankyo